FeesSafety
Pluang+

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Company Fundamentals
21 Nov 2026, 19:17 WIB
The Motley Fool
View Source
Bullish
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and notable improvements in health markers. This success could lead to label expansion for younger patients, tapping into a potential U.S. market of over five million adolescents with obesity. If Eli Lilly captures 20% of this market, it could generate an additional $6.5 billion in annual revenue. The company is also exploring use in children aged 6 to 11, further expanding its addressable market despite competition from Novo Nordisk's Wegovy.

Eli Lilly holds a market cap of $1.20 trillion and a dividend yield of 0.51% as of Nov 22, 2026 00:31 WIB on Pluang, with a typical hold time of 95 days and balanced buy-sell activity. Meanwhile, competitor Novo Nordisk has a market cap of $171.04 billion and a higher dividend yield of 4.75%, but a larger sell bias at 78% on Pluang. Eli Lilly's stock price was $1,347.11, down 0.30% on the day, reflecting steady investor interest amid its expanding obesity drug market potential.

More News (LLY)

AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie and Eli Lilly are key pharmaceutical players with distinct strengths for 2027. AbbVie focuses on immunology and aesthetics with solid cash flow and a lower valuation, making it a value pick. Eli Lilly dominates metabolic health with rapid reve...

Market News
Bullish
1 day ago
$1,000 invested in Eli Lilly 10 years ago is now worth over $20,500, driven by blockbuster diabetes and obesity drugs.

$1,000 invested in Eli Lilly 10 years ago is now worth over $20,500, driven by blockbuster diabetes and obesity drugs.

Eli Lilly's stock has surged dramatically over the past decade, with a $1,000 investment growing to more than $20,500, thanks mainly to its diabetes and obesity drugs like Mounjaro (tirzepatide) and Zepbound. The company, now valued at over $1.2 tril...

Company Fundamentals
Bullish
2 days ago
Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.

Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.

Eli Lilly reported a 53% volume increase in Q3 despite a 15% drop in realized prices, prompting management to raise 2026 revenue guidance to $91–92 billion. The company's promising drug Retatrutide, currently in Phase 3 trials, supports future growth...

Analyst Insights
Bullish
2 days ago
Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

The global pharmaceutical market is projected to grow from $1.88 trillion in 2026 to $3.20 trillion by 2035, driven mainly by obesity and oncology drugs. The U.S. market, holding 42% of the global share, faces new tariffs linked to pricing deals and ...

Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App